Oncology Central

An update on current standards and clinical trials in systemic therapy for stage III NSCLC


Despite a number of recent breakthroughs in the treatment of metastatic NSCLC, the management of patients with stage III disease remains a challenge. The standard of care remains concurrent chemoradiation, and though a number of treatment strategies have been studied, no novel approach has clearly shown a consistent benefit.

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.